AOD-9604 Australia: Human Trials, TGA Status and WADA Rules

Overview: Evidence-led AOD-9604 profile covering human weight-loss trials, Schedule 4 status in Australia, the 2026 WADA prohibition and research limitations.

AOD-9604 is a modified fragment of human growth hormone that was investigated as an anti-obesity drug. Animal experiments produced signals involving fat metabolism, but the human development programme did not establish a reliable weight-loss benefit. Australian scheduling and anti-doping rules also matter: AOD-9604 is a Schedule 4 substance in the current Poisons Standard and is specifically named by the World Anti-Doping Agency as a prohibited growth-hormone fragment.

This profile separates preclinical mechanisms, human trial history, Australian regulatory status and sporting rules. It does not provide purchasing, dosing or administration instructions.

AOD-9604 at a glance

What AOD-9604 was designed to test

Human growth hormone has broad effects on growth, metabolism and signalling. AOD-9604 was designed from a short C-terminal region associated with lipolytic research. The development hypothesis was that a fragment might influence fat metabolism without producing the wider growth-promoting and glucose effects associated with full-length growth hormone.

That is a mechanistic hypothesis, not evidence of clinical efficacy. A molecule can affect a pathway in cells or animals and still fail to produce a useful, reproducible outcome in people.

Preclinical evidence: a biological signal, not a human result

Early studies in obese rodents reported reduced body-weight gain, increased fat oxidation and changes in lipolytic sensitivity after AOD-9604 exposure. Researchers also reported that the fragment did not behave identically to full-length growth hormone in the experimental systems studied.

These experiments helped justify human development, but they have important limits:

• rodent energy balance and dosing conditions do not replicate long-term human obesity;
• changes in fat oxidation are not equivalent to durable loss of body weight or improvement in health outcomes;
• laboratory routes, exposures and controls may differ from products promoted online;
• animal findings cannot establish human safety for repeated use.

Primary preclinical sources include Ng and colleagues’ metabolic study and Heffernan and colleagues’ chronic-treatment study in mice.

Human evidence: what the programme did and did not establish

AOD-9604 progressed into early human obesity studies. Published reviews describe a short trial in which one tested group lost more weight than placebo, but the effect was not consistently dose-dependent. An isolated favourable dose result is weaker evidence when a biological gradient is absent and later development does not reproduce a useful effect.

The most important outcome is the later programme-level result. The TGA’s scheduling-decision record states that AOD-9604 was initially developed as an anti-obesity drug but that the programme was discontinued in 2007 because the clinical trials did not show a meaningful weight-loss outcome across the trial population. A published review describes a 24-week study involving 536 participants that failed to demonstrate significant weight loss.

This history means it is misleading to present AOD-9604 as a clinically proven “fat-burning peptide”. The strongest defensible summary is:

• there was a plausible experimental rationale;
• preclinical studies produced metabolic signals;
• early human testing did not translate into a consistent, meaningful efficacy result;
• the development programme was discontinued;
• modern long-term comparative and outcomes evidence is absent.

See the TGA scheduling decision reasons and the peer-reviewed review of obesity pharmacotherapy development.

What the safety literature can support

A published safety review pooled information from six randomised, placebo-controlled AOD-9604 studies. That work is useful for identifying the events observed under the studied conditions, but it does not convert an ineffective development programme into an effective therapy. Nor does a limited trial safety database establish the safety of every route, formulation, exposure or duration promoted outside those trials.

The TGA’s scheduling deliberations specifically noted limited data for repeated intravenous or subcutaneous exposure and for long-term oral exposure above the conditions studied. This is why “no signal in a small early study” should not be rewritten as “proven safe”.

Published AOD-9604 safety and tolerability review

AOD-9604 in Australia: Schedule 4 is not marketing approval

The Therapeutic Goods (Poisons Standard—October 2026) Instrument lists AOD-9604 in Schedule 4. Schedule 4 covers prescription-only medicines and prescription animal remedies and imposes controls on supply. Appendix D, clause 5, also names AOD-9604 (CAS No. 221231-10-3), at item 3.

Scheduling answers a different question from ARTG registration:

Consumers and researchers should search the ARTG for the exact product, sponsor and indication rather than treating a Schedule 4 entry as an approval badge.

AOD-9604 and the 2026 WADA Prohibited List

The 2026 WADA Prohibited List names AOD-9604 as an example of a growth-hormone fragment under S2.2.3. Substances in section S2 are prohibited at all times, in and out of competition.

“Experimental”, “research use” or “not a full hormone” does not remove an athlete’s anti-doping responsibility. Athletes should use the official list and qualified anti-doping medical channels rather than relying on a product description.

Why “10 mg”, “purity” and a certificate do not answer efficacy

Searches for AOD-9604 often include a vial strength or a purity percentage. Those details do not establish clinical benefit. A label quantity is not a trial result, and an HPLC peak-area percentage does not by itself establish identity, sterility, endotoxin control, biological activity or lawful supply.

Our HPLC chromatogram guide explains why peak area should not be treated as a universal purity certificate, and the certificate-of-analysis guide shows which claims require orthogonal evidence.

Frequently asked questions

Does AOD-9604 work for weight loss?

Preclinical studies showed metabolic signals, and some early human results were investigated, but the clinical programme did not establish consistent meaningful weight loss across the study population. Development for obesity was discontinued.

Is AOD-9604 approved in Australia?

AOD-9604 is listed in Schedule 4 of the current Poisons Standard. That scheduling status is not the same as ARTG registration or approval of a specific product for weight loss. Check the ARTG for the exact product and indication.

Is AOD-9604 a growth hormone?

It is a modified fragment derived from a region of human growth hormone, not full-length human growth hormone. That distinction does not establish efficacy or remove regulatory and anti-doping controls.

Is AOD-9604 banned by WADA?

Yes. The 2026 Prohibited List specifically names AOD-9604 among prohibited growth-hormone fragments.

Does “99% HPLC purity” prove a product is safe?

No. HPLC peak area is method-dependent and does not by itself prove identity, sterility, endotoxin status, dose accuracy, absence of all contaminants or clinical safety.

Evidence map and sources

• Australian Poisons Standard—October 2026
• TGA scheduling decision reasons for AOD-9604
• WADA 2026 Prohibited List
• Preclinical metabolic study in obese rats
• Preclinical chronic-treatment study in mice
• Peer-reviewed obesity pharmacotherapy review
• Safety and tolerability review

Reviewed 29 September 2026. The profile will be updated if the Poisons Standard, ARTG status, WADA list or peer-reviewed human evidence changes.